LEADER 01354nam  2200361Ia 450 
001 9910698830103321
005 20090527105754.0
035   $a(CKB)5470000002397567
035   $a(OCoLC)352878758
035   $a(EXLCZ)995470000002397567
100   $a20090527d2003      ua             0
101 0 $aeng
135   $auran|||||||||
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 00$aGuidance for industry$b[electronic resource] $esource animal, product, preclinical, and clinical issues concerning the use of xenotransplantation products in humans
210  1$aRockville, MD :$cU.S. Dept. of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research,$d[2003]
215   $aii, 60 pages $cdigital, PDF file
300   $aTitle from PDF title page (viewed on May 27, 2009).
300   $a"Final guidance".
300   $a"April 2003".
320   $aIncludes bibliographical references (pages 56-60).
517   $aGuidance for industry 
606   $aXenografts$xGovernment policy$zUnited States
615  0$aXenografts$xGovernment policy
712 02$aCenter for Biologics Evaluation and Research (U.S.)
801  0$bGPO
801  1$bGPO
906   $aBOOK
912   $a9910698830103321
996   $aGuidance for industry$93434577
997   $aUNINA